NCT01677455已完成2 期
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 51
- 试验地点
- 3
- 主要终点
- Objective response rate
研究概览
简要总结
The purpose of this study is to determine if ganetespib (STA-9090) is effective in the treatment of patients with HER2+ or triple negative breast cancer who have not received prior systemic treatment in the metastatic setting.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Pathologically confirmed diagnosis of invasive breast cancer.
- •Stage IV disease.
- •Documented HER2 and hormonal receptor status per protocol, ER/PR+ patients must be refractory to at least one prior hormonal treatment.
- •ECOG Performance status 0-
- •Measurable disease per RECIST (1.1).
- •Adequate hematological function per protocol.
- •Adequate hepatic function per protocol.
- •Adequate renal function per protocol.
- •Negative serum pregnancy test at study entry for patients of childbearing potential.
- •Ability to understand and sign written consent and to comply with the study protocol.
排除标准
- •Presence of active or untreated CNS metastases as determined by MRI/CT scan performed during screening.
- •Active malignancies other than MBC within the last 5 years except adequately treated in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin.
- •Bone as the only site of metastatic disease from breast cancer.
- •Prior radiotherapy to the only area of measurable disease. NOTE: Radiotherapy to a limited area other than the sole site of measurable disease is allowed, if received prior to initiation of ganetespib treatment. Patients must have completed treatment and recovered from all acute treatment-related toxicities prior to administration of first dose of ganetespib.
- •Pregnancy or lactation.
- •Known serious cardiac illness.
- •Uncontrolled intercurrent illness per protocol.
- •Other severe acute or chronic medical condition or abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, or that in the judgment of the investigator would make the patient inappropriate for entry into the study.
研究组 & 干预措施
HER2+ breast cancer
Experimental
干预措施: ganetespib (Drug)
Triple negative breast cancer
Experimental
Closed to enrollment
干预措施: ganetespib (Drug)
ER/PR+ Refractory to Prior Hormonal Treatment
Experimental
干预措施: ganetespib (Drug)
结局指标
主要结局
Objective response rate
时间窗: Week 12
Objective response rate is based on RECIST criteria
次要结局
- Duration of response and progression free survival(Every six weeks until progression)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)Non Small Cell Lung CancerNCT01031225Synta Pharmaceuticals Corp.113
终止
2 期
Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung CancerNon-small Cell Lung Cancer Stage IIIBNon-small Cell Lung Cancer Stage IVNon-small Cell Lung Cancer MetastaticNCT01348126Synta Pharmaceuticals Corp.385
进行中（未招募）
1 期
A Randomized, Phase IIb/III Study of Ganetespib (STA-9090) in Combination with Docetaxel versus Docetaxel alone in Subjects with Stage IIIb or IV Non-Small Cell Lung CancerEUCTR2011-001084-42-HUSynta Pharmaceutical Corp.385
进行中（未招募）
不适用
A study to assess the effect of Ganetespib (study drug) in combination with Docetaxel versus Docetaxel alone in patients with advanced Non-Small Cell Lung Canceron-Small Cell Lung CancerMedDRA version: 14.0Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001084-42-ESSynta Pharmaceutical Corp.740
进行中（未招募）
不适用
A study to assess the effect of Ganetespib (study drug) in combination with Docetaxel versus Docetaxel alone in patients with advanced Non-Small Cell Lung Canceron-Small Cell Lung CancerMedDRA version: 17.0Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBSystem Organ Class: 100000004864MedDRA version: 17.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2011-001084-42-DESynta Pharmaceutical Corp.900